Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Donafenib Combined With Sintilimab for Advanced HCC: a Single-arm, Single-center, Prospective Study

NCT05162352 is registered in ClinicalTrials.gov with Second Affiliated Hospital of Guangzhou Medical University as lead sponsor.

NCT NCT05162352
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05162352 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Donafenib Combined With Sintilimab for Advanced HCC: a Single-arm, Single-center, Prospective Study
Lead sponsor
Second Affiliated Hospital of Guangzhou Medical University
Phase
Phase 2
Overall status
Completed
Start date
December 4, 2021
Completion date
August 31, 2023
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma